Amgen Surges on Strong Earnings but Analysts Disagree on Valuation

Amgen (AMGN) has seen its share price surge following strong second quarter results and updates to its drug portfolio, with analyst Argus lifting its target price to $460 from $375 while maintaining a Buy rating.

The company's recent momentum has led some analysts to reassess the business, but Simply Wall St suggests that Amgen may be 20.5% overvalued around $360 per share.

A discounted cash flow (DCF) model used by Simply Wall St estimates a future cash flow value of $691.35 for Amgen, indicating that the company could be trading at a discount.

This divergent view highlights the complexity of valuing Amgen and underscores the importance of carefully considering multiple perspectives when evaluating the stock.